secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2026-08-05T20:10:04+00:00
Accession:  0001193125-26-335098
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics reports Q2 2026 net loss of $43.4M; positive interim data for TN-201 and TN-401
--------------------------------------------------------------------------------

- Net loss of $43.4M ($0.20 loss per share) vs $23.3M loss in Q2 2025; includes $21.8M impairment charge from GMMC lease termination.
- Cash and equivalents $78.1M as of June 30, 2026; runway extended through Q3 2027 including $10M Alnylam upfront.
- Positive interim data from TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) trials: all evaluable patients showed improvements in hypertrophy and electrical stability.
- Additional data and regulatory discussions on pivotal trial plans for TN-201 and TN-401 expected in Q4 2026.
- Appointed Eric Hyllengren as CFO effective July 13, 2026; TN-301 Phase 2 trial expected to start 2H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/0001193125-26-335098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/tnya-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer